Juvenile Idiopathic Arthritis (JIA) Treatments

Find Juvenile Idiopathic Arthritis (JIA) Treatments

Generic Name

Adalimumab

Brand Names
Adalimumab-aacf, Humira
FDA approval date: December 31, 2002
Form: Kit

What is Adalimumab-aacf (Adalimumab)?

Adalimumab-aacf is a tumor necrosis factor blocker indicated for: Rheumatoid Arthritis .
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

Summary: HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfo...

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Summary: This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.

Pragmatic, Open-Label, Two-Stage, Pilot Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

Summary: Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).

Brand Information